NIAID’s Comprehensive Support Mechanisms for Antibiotic Development

  15 June 2020

The National Institute of Allergy and Infectious Diseases (NIAID) recognizes the continuing threat of antimicrobial resistance and the need to develop new therapeutics and strategies to combat multidrug resistant organisms. NIAID leverages multiple mechanisms to help support antibiotic developers struggling in the “valley of death” of preclinical antibiotic development. The Division of Microbiology and Infectious Diseases’ (DMID) preclinical services are a comprehensive set of services to facilitate efforts to develop vaccines, diagnostics, and therapeutics for a broad array of bacterial, viral, fungal, and parasitic pathogens. These services are available to investigators worldwide at no charge.

Further reading: ACS Publications
Author(s): Erin M. Zeituni and Erica L. Raterman Cite
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Ambassador Network

Join the AMR Insights Ambassador Network today!

Connect to over 550 AMR professionals and students in 60 countries!

More information
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!
Popup Plugin